Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 392 - 392

Published: April 8, 2025

(1) Background: Clinical evidence has raised concerns regarding a potential link between COVID-19 mRNA-based vaccines and the occurrence of thromboembolic events. So far, no research explored effects this possible interaction in cancer patients undergoing active treatment. We leveraged prospective monitoring from Vax-On-Third-Profile study to examine development venous thromboembolism (VTE) after third dose mRNA-BNT162b2 (tozinameran) its association with antibody lymphocyte responses. (2) Methods: Patients who had received tozinameran not experienced any VTE previous 30 days were eligible. A serological evaluation was conducted before booster vaccination (timepoint-1) four weeks thereafter (timepoint-2) measure titers against SARS-CoV-2 spike protein, as well determine absolute counts T-helper cells, T-cytotoxic B NK cells. Data acquired November 2021 October 2022 analyzed 2023. (3) Results: The present involved 429 given 26 September 2021. Among treatments interest, 109 (25.4%) targeted therapy, 111 (25.9%) cytotoxic chemotherapy, 39 (9.1%) immune checkpoint inhibitors, 21 (4.9%) endocrine (7.0%) combination chemotherapy agents eight preceding dosing. In addition, 119 (27.7%) discontinued systemic therapy for at least 12 accounted reference subgroup. After median follow-up time 10.6 (95% CI 8.1-11.7) months, we observed 31 events general population, an overall incidence rate 7.2% 5.0-10.1). immunization 99 85-112) days. univariate comparison, exposed therapies (11.3% [95% 6.0-18.9]; p = 0.030) or inhibitors (16.2% 6.2-32.0]; 0.012) significantly higher than cohort (3.4% 0.9-8.5]). Univariate analysis responses showed that only dynamic changes pertaining cell distributions correlated occurrence. Multivariate regression confirmed high-level response (OR 6.10 [9% 2.16-17.21]; 0.001), history 9.81 [3.99-24.13]; < presence central catheter 5.02 1.84-13.67]; 0.002) independently associated increased risk VTE. (4) Conclusions: This provides unprecedented have developing tozinameran, regardless type therapy. specific pattern appears increase risk, underlying dysregulation causal cofactor. These findings emphasize need additional periodic patients.

Language: Английский

---

Serological response and immune‐related adverse events following COVID‐19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis

Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 34(1)

Published: Nov. 28, 2023

Abstract With the popularity of Coronavirus disease 2019 (COVID‐19) vaccine and development vaccination strategies, impact COVID‐19 on cancer patients receiving immune checkpoint inhibitors (ICIs) is still unclear. In systematic review meta‐analysis with ICIs, we assessed serological response vaccine, explored risk related adverse events (irAEs). We searched PubMed, EMBASE Cochrane Library as 10 June 2023, included who received ICIs vaccine. The include cohort study, cross‐sectional study case report. outcome response, Spike‐specific T‐cell irAEs rare events. When possible, data were analysed by random effect analysis, statistical heterogeneity was Q‐test I 2 statistics. sources through L’Abbe plots, Galbraith radial sensitivity analysis. publication bias evaluated Egger's, Begg's linear regression test funnel plot, further trim fill method. 27 studies eligible (19 studies, 1 7 reports), involving 8331 (with 4724 ICIs). Most used mRNA (BNT162b2 or mRNA‐1273). Compared chemotherapy, significantly more likely to have seroconversion (RR = 1.05, 95%CI 1.01–1.10, P 0.02). There no statistically significant differences in rates when comparing controls without 0.95, 95% CI 0.89–1.01, 0.09) targeted therapy 0.79–1.39, 0.75). incidence before after (21.96%, 16.66%–28.94%) (14.88%, 8.65%–25.57%), respectively. most common endocrine abnormalities, skin disorders, etc. certainty evidence low compared those very versus cancer. Cancer treated seem be able receive safely increasing irAEs.

Language: Английский

---

Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: June 5, 2024

To investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether increases incidence ICIPI. We conducted a retrospective study 256 stage IV patients treated with ICIs at The First Affiliated Hospital Anhui Medical University from January 2020 to November 2022. Data collected included enzyme levels, treatment outcomes, vaccination status. Statistical significance was determined using χ2 test Kaplan-Meier method (p < .05). Compared control group, vaccinated group .0001) elevated levels = .044) demonstrated higher disease rates, indicating direct benefit monitoring outcomes. Additionally, longer overall survival versus unvaccinated (23.9 months [95% CI, 22.3–25.5] vs 23.6 21.1–26.2], HR 0.45 0.24–0.86], p .015) progression-free (17.2 14.3–20.1] 13.7 11.3–16.1], 0.54 0.36–0.82], .004). Importantly, analysis revealed no significant association between .46). Monitoring enzymes can effectively evaluate therapeutic impact in ICIs. Patients against experience better immunotherapy outcomes without an increased risk

Language: Английский

---

Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer, Journal Year: 2024, Volume and Issue: 12(11), P. e009931 - e009931

Published: Nov. 1, 2024

Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction them obtain response, and clinical benefit from these treatments is often difficult to predict. The aim our study unveil potential implications antibody response previous viral infections in predicting ICBs NSCLC. Sera treated alone, chemotherapy (CT) or combination CT-ICBs were analyzed VirScan (CDI Labs, USA), high-throughput method that comprehensively analyzes epitope-level antiviral IgG antibodies via programmable phage display immunoprecipitation sequencing.Total number unique positive peptides (tUP) was defined as total non-overlapping "is hit" for each patient. Overall, 387 included. Of them, 129 66 195 CT alone. 90 out alone received subsequent line treatment, while administered upfront therapies.A higher tUP correlated improved overall survival ICBs, confirmed multivariate model (HR 0.43, 95% CI 0.24, 0.79, p=0.006), it not those (p=0.8) (p=0.1).tUP programmed death-ligand 1 (PD-L1) expression, at transcriptome level several immune-related pathways, particularly involving B cells. A recognized by serum might reflect increased immune fitness, resulting outcomes

Language: Английский

---